Conditioning regimens used for allogeneic transplantation for solid tumors
Authors . | Nonmyeloablative conditioning regimens . | Chimerism results . |
|---|---|---|
| Childs et al43 | Fludarabine 25 mg/m2 × 5 d, cyclophosphamide 60 mg/kg × 2 d | 8 of 19 patients needed DLI for T-cell chimerism, disease control or both |
| Rini et al45 | Fludarabine 30 mg/m2 × 5 d, cyclophosphamide 2 g/m2 × 2 d | 5 of 12 patients had achieved 100% donor chimerism on d 100 |
| Pedrazzoli et al46 | Fludarabine 30 mg/m2 × 4 d, cyclophosphamide 30 mg/kg × 2 d | 13 of 17 patients had achieved 100% donor chimerism on d 90 |
| McDermott et al48 | Fludarabine 25 mg/m2 × 5 d, cyclophosphamide 60 mg/kg × 2 d | 6 of 7 patients had achieved > 95% T-cell chimerism on median d 75 |
| Sandmaier et al49 | Fludarabine 30 mg/m2 × 3 d, total body irradiation 2 Gy × 1 d | 1 of 5 patients had graft rejection; 4 of 5 patients had a median T-cell chimerism rate of 73% on d 84 |
| Hentschke et al50 | Fludarabine 30 mg/m2 × 3 d (related donor) or 30 mg/m2 × 5 d (unrelated donor), total body irradiation 2 Gy × 1 d, ATG 2 mg/kg × 2 d (unrelated donor) | 12 of 18 patients had complete donor chimerism, 2 had graft failure, 1 had marrow aplasia, and 3 had mixed chimerism |
| Bregni et al47 | Fludarabine 30 mg/m2 × 2 d, cyclophosphamide 30 mg/kg × 2 d, thiotepa 10 mg/kg × 1 d (for BC) or 5 mg/kg × 1 d (for RCC) | 12 of 13 patients had > 80% donor chimerism on d 60 |
| Hori et al52 | Fludarabine 30 mg/m2 × 6 d, busulfan 4 mg/kg × 2 d, ATG 2.5 mg/kg × 2 d | All 8 patients had 100% complete donor chimerism |
| Makimoto et al51 | Fludarabine 30 mg/m2 (cladribine 0.11 mg/kg for the first 3 patients) × 6 d, busulfan 4 mg/kg × 2 d, ATG 2.5 mg/kg × 2 d | 13 of 14 patients had complete donor chimerism |
| Blaise et al53 | Fludarabine 180 mg/m2 (total dose), busulfan 8 mg/kg (total dose), ATG 2.5-10 mg/kg | 80% of evaluable patients had full donor chimerism |
| Ueno et al (current study) | Fludarabine 30 mg/m2 × 5 d (for BC) or 25 mg/m2 × 5 d (for RCC), melphalan 70 mg/m2 × 2 d | 1 of 23 patients had early death; 22 of 23 patients had 100% donor chimerism on d 30 and d 100 |
Authors . | Nonmyeloablative conditioning regimens . | Chimerism results . |
|---|---|---|
| Childs et al43 | Fludarabine 25 mg/m2 × 5 d, cyclophosphamide 60 mg/kg × 2 d | 8 of 19 patients needed DLI for T-cell chimerism, disease control or both |
| Rini et al45 | Fludarabine 30 mg/m2 × 5 d, cyclophosphamide 2 g/m2 × 2 d | 5 of 12 patients had achieved 100% donor chimerism on d 100 |
| Pedrazzoli et al46 | Fludarabine 30 mg/m2 × 4 d, cyclophosphamide 30 mg/kg × 2 d | 13 of 17 patients had achieved 100% donor chimerism on d 90 |
| McDermott et al48 | Fludarabine 25 mg/m2 × 5 d, cyclophosphamide 60 mg/kg × 2 d | 6 of 7 patients had achieved > 95% T-cell chimerism on median d 75 |
| Sandmaier et al49 | Fludarabine 30 mg/m2 × 3 d, total body irradiation 2 Gy × 1 d | 1 of 5 patients had graft rejection; 4 of 5 patients had a median T-cell chimerism rate of 73% on d 84 |
| Hentschke et al50 | Fludarabine 30 mg/m2 × 3 d (related donor) or 30 mg/m2 × 5 d (unrelated donor), total body irradiation 2 Gy × 1 d, ATG 2 mg/kg × 2 d (unrelated donor) | 12 of 18 patients had complete donor chimerism, 2 had graft failure, 1 had marrow aplasia, and 3 had mixed chimerism |
| Bregni et al47 | Fludarabine 30 mg/m2 × 2 d, cyclophosphamide 30 mg/kg × 2 d, thiotepa 10 mg/kg × 1 d (for BC) or 5 mg/kg × 1 d (for RCC) | 12 of 13 patients had > 80% donor chimerism on d 60 |
| Hori et al52 | Fludarabine 30 mg/m2 × 6 d, busulfan 4 mg/kg × 2 d, ATG 2.5 mg/kg × 2 d | All 8 patients had 100% complete donor chimerism |
| Makimoto et al51 | Fludarabine 30 mg/m2 (cladribine 0.11 mg/kg for the first 3 patients) × 6 d, busulfan 4 mg/kg × 2 d, ATG 2.5 mg/kg × 2 d | 13 of 14 patients had complete donor chimerism |
| Blaise et al53 | Fludarabine 180 mg/m2 (total dose), busulfan 8 mg/kg (total dose), ATG 2.5-10 mg/kg | 80% of evaluable patients had full donor chimerism |
| Ueno et al (current study) | Fludarabine 30 mg/m2 × 5 d (for BC) or 25 mg/m2 × 5 d (for RCC), melphalan 70 mg/m2 × 2 d | 1 of 23 patients had early death; 22 of 23 patients had 100% donor chimerism on d 30 and d 100 |
ATG indicates antithymocyte globulin.